Tamoxifen: adverse effects and possible interactions with antidepressants in patients with breast cancer
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The publication are distributed under the Creative Commons Attribution-NonCommercial-Non Derivatives 4.0 International license (CC BY-NC-ND 4.0). The rights of the works published in this journal are the property of the author and they are free to distribute and disseminate them, as long as the source is correctly cited, no derivative works are generated and these acts do not have commercial purposes.
Main Article Content
Abstract
Breast cancer is the most frequently diagnosed malignancy in women. Tamoxifen is the adjuvant drug of choice in the endocrine treatment of estrogen receptor-positive breast cancer. It has effects that are very useful with respect to the vaginal epithelium and bone, in addition, it is cardioprotective. On the other hand, it should be noted that after the diagnosis of the disease, there are notable physical and psychological changes that have a great impact on the patient and that, in many cases, is linked to the appearance of depression. The aim of this work was to analyze the evidence regarding the possible interactions between tamoxifen and different antidepressants, as well as their adverse effects in breast cancer patients receiving tamoxifen treatment. For this, a systematic review of the articles published in the last 10 years in the Science Direct, Dialnet, Scielo, Medigraphic and PubMed databases was carried out. After the final selection of 12 documents, the results indicate that the choice of antidepressant in the case of women with breast cancer undergoing treatment with tamoxifen should be made based on the profile, side effects, and possible drug interaction potential. It is essential to pay special attention to the importance of the interactions that can occur between tamoxifen and antidepressants, since this interaction can have an impact on the prognosis of breast cancer and the indication of antidepressants arises from non-oncology specialists. In short, it is essential to take into account that there is no clinical evidence that supports prescribing one antidepressant instead of another with respect to their efficacy and safety, therefore attention must be paid to the different interactions that may arise.
References
Álvarez, C. M., Gispert, M. M., Galindo, A. L., Palacios, E. M., Aldeguer, L. F., y Méndez, J. I. S. (2020). Empleo actual de la hormonoterapia neoadyuvante en cáncer de mama: resultados de una encuesta realizada en España. Revista de Senología y Patología Mamaria, 33(1), 23 - 31.
Berrospi-Reyna, S., Herencia-Souza, M., y Soto, A. (2017). Prevalencia y factores asociados a la sintomatología depresiva en mujeres con cáncer de mama en un hospital público de Lima, Perú. Acta médica peruana, 34(2), 95 - 100.
Camejo-Martínez, N., Castillo-Leska, C., Artagaveytia-Cóppola, N. A., Hernández-Ibero, A. L., Amarillo-Hernández, D. L., Apud-Yumati, P. S., Melo-Ramundo, F., y Delgado-Pebe, L. B. (2021). Adhesión a la hormonoterapia adyuvante en pacientes con cáncer de mama. Revista Médica del Instituto Mexicano del Seguro Social, 57(6), 357-363.
Dalbert, D. B., Rodríguez de la Peña, M. M., Figueredo, A., Mural, J., Bartt, O., Subiela, R., Rossi, C., y Bazán, G. (2013). Tamoxifeno y afecciones endometriales en pacientes con cáncer de mama. Medicina (Buenos Aires), 73(2), 97 - 103.
García, P. B., y Algar, M. J. M. (2016). Tratamiento farmacológico de la depresión en cáncer. Psicooncología, 13 (2), 249 - 270.
Hemer-Cera, M., Donado-Botero, R., Barcasnegras-Deavila, C., García-Osorio, A., Turcios-Ordoñez, D., Hernández-Lastra, Á., Peñuela-Espalza, M., y Floréz-García, V. (2021). Hiperplasia endometrial asociada al uso del tamoxifeno en pacientes con cáncer de mama en Barranquilla. CES Medicina, 35(1), 16 - 25.
Irarrázaval, M. E. (2011). Tamoxifeno y antidepresivos: ¿Antagonistas en la prevención del cáncer de mama? Rev Med Chile, 139, 89 - 99.
Irarrázaval, M. E., y Gaete, L. (2016). Elección del mejor antidepresivo en pacientes con cáncer de mama en tratamiento con tamoxifeno: revisión de la evidencia básica y clínica. Revista médica de Chile, 144(10), 1326 - 1335.
Ministerio de Salud, Subsecretaria de Salud Pública, División de Prevención y Control de Enfermedades, Departamento de Salud Mental., (2017). Guía Clínica: Abordaje de la depresión en mujeres con cáncer de mama. Santiago: Minsal.
Rubio, M. A. L., López, P. J. T., López, A. M., y Moya, A. (2020). Salud sexual en mujeres con cáncer de mama tratadas con Tamoxifeno. Journal of Negative and No Positive Results: JONNPR, 5(12), 1528 - 1537.
Sánchez, A. V. A., Ortiz, M. J. M., Madrona, A. P., González, C. Á., Ascencio, R. S., y Cerezuela, P. (2013). Prescripción conjunta de antidepresivos y tamoxifeno: una cuestión a tener en cuenta. Revista de Senología y Patología Mamaria, 26(4), 134 -137.
Souza, B. F. D., Moraes, J. A. D., Inocenti, A., Santos, M. A. D., Silva, A. E. B. D. C., y Miasso, A. I. (2014). Mujeres con cáncer de mama en tratamiento con quimioterapéuticos: síntomas depresivos y adhesión al tratamiento. Revista LatinoAmericana de Enfermagem, 22, 866 - 873.